Our Approach

Ardelyx develops:

  • Drugs that target proteins found in the gut whose activities affect the entire body
  • Drugs that are not absorbed, enabling them to achieve systemic efficacy while avoiding systemic toxicity and side effects

What we do

Targeted Therapeutic Areas

Ardelyx has established a unique approach to drug development with programs targeting gut transporters, receptors, and enzymes

Therapeutic Areas

Products

Program Indication Preclin Phase 1 Phase 2 Phase 3
RDX5791 Chronic Kidney Disease * * * *
  End Stage Renal Disease * * * *
  Heart Failure * * * *
  IBS-C, Constipation * * * *
RDX002 Chronic Kidney Disease * * * *
RDX009 Type 2 Diabetes * * * *
RDX013 Hyperkalemia CKD * * * *